Drug Trial Radar · NCT03447769
Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A
Last checked: Nov 20, 2026Latest source record: Oct 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,382
Actual
Start
Mar 16, 2018
Primary completion
Mar 17, 2022
Study completion Feb 7, 2023
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 27, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of the study was to compare the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages II -IIIA according to the 8th edition of the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) and the subset of IIIB (T\>5cm N2 disease) completely resected (R0) non-small cell lung cancer (NSCLC).
Conditions
- Non-Small Cell Lung Cancer
Interventions
CanakinumabDrug
200 mg of canakinumab administered subcutaneously on day 1 of every 21-day cycle for 18 cycles. Canakinumab solution for injection was provided by Novartis as ready-to-use pre-filled syringes to be administered by study personnel.
PlaceboDrug
Placebo administered subcutaneously on day 1 of every 21-day cycle for 18 cycles. Placebo solution for injection was provided by Novartis as ready-to-use pre-filled syringes to be administered by study personnel.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease Free Survival (DFS) by Local InvestigatorTime frame: Up to approximately 4 years
Locations
283 sites in 41 countries. Site status is shown where the registry gives one.
Highlands Oncology Group .
Fayetteville, Arkansas
Cancer and Blood Specialty Clinic
Los Alamitos, California
University of California at Los Angeles
Los Angeles, California
VA Palo Alto Health Care System CRLX030A2301
Palo Alto, California
Sansum Clinic
Santa Barbara, California
Rocky Mountain Cancer Centers Denver-Mdtn(Bone&MarrowTransp)
Longmont, Colorado
Florida Cancer Specialists
Fort Myers, Florida
Advanced Medical Specialties Drug Ship - 2
Miami, Florida
Florida Cancer Affiliates of Ocala
Ocala, Florida
Florida Cancer Specialists North
St. Petersburg, Florida
Florida Cancer Specialists
West Palm Beach, Florida
Rush University Medical Center Regulatory
Chicago, Illinois
Cancer Center of Kansas Dept.ofCancerCtr.ofKansas
Wichita, Kansas
VA Nebraska-W IA Health Care System .
Omaha, Nebraska
Louis Stokes Cleveland Department of Veterans Affairs MC .
Cleveland, Ohio
Oncology Associates of Oregon, PC
Eugene, Oregon
Chattanooga Oncology and Hematology Associates PC Chattanooga Oncology
Chattanooga, Tennessee
Sarah Cannon Research Institute
Nashville, Tennessee
Texas Oncology MamieMcFaddenWardCtr
Dallas, Texas
Virginia Cancer Specialists Fairfax Northern Virginia
Fairfax, Virginia
Oncology and Hematology Associates of Southwest Virginia Inc .
Salem, Virginia
Novartis Investigative Site
Córdoba, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Mar del Plata, Buenos Aires, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
Rosario, Sante Fe, Argentina
Novartis Investigative Site
Graz, Austria
Novartis Investigative Site
Klagenfurt, Austria
Novartis Investigative Site
Krems, Austria
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Londrina, Paraná, Brazil
Novartis Investigative Site
Teresina, Piauí, Brazil
Novartis Investigative Site
Barretos, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Edmonton, Alberta, Canada
Showing 40 of 283 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.